CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Dose-escalation Trial to Evaluate Haploidentical / Allogeneic Natural Killer Group 2D Ligand (NKG2DL)-Targeting Chimeric Antigen Receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in Subjects With Relapsed or Refractory Solid Tumour

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04107142
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:33.689149+00:00
Published At: 2019-09-27T00:00:00+00:00
Record Updated At: 2019-09-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Colorectal Cancer", "Triple Negative Breast Cancer", "Sarcoma", "Nasopharyngeal Carcinoma", "Prostate Cancer", "Gastric Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-09-27"
protocolSection.identificationModule.nctId: "NCT04107142"
protocolSection.identificationModule.officialTitle: "A Phase I Dose-escalation Trial to Evaluate Haploidentical / Allogeneic Natural Killer Group 2D Ligand (NKG2DL)-Targeting Chimeric Antigen Receptor-grafted Gamma Delta (\u03b3\u03b4) T Cells (CTM-N2D) in Subjects With Relapsed or Refractory Solid Tumour"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.